CN116997339A - 作为治疗剂的cGAS活性抑制剂 - Google Patents

作为治疗剂的cGAS活性抑制剂 Download PDF

Info

Publication number
CN116997339A
CN116997339A CN202280019484.7A CN202280019484A CN116997339A CN 116997339 A CN116997339 A CN 116997339A CN 202280019484 A CN202280019484 A CN 202280019484A CN 116997339 A CN116997339 A CN 116997339A
Authority
CN
China
Prior art keywords
pyrrolidine
methylbenzofuran
pyrimidin
carboxylic acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280019484.7A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·G·洛厄里
梅拉·库马尔
马修·博克瑟
大卫·马洛尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belbrook Laboratories LLC
Original Assignee
Belbrook Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belbrook Laboratories LLC filed Critical Belbrook Laboratories LLC
Publication of CN116997339A publication Critical patent/CN116997339A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280019484.7A 2021-02-11 2022-02-11 作为治疗剂的cGAS活性抑制剂 Pending CN116997339A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148201P 2021-02-11 2021-02-11
US63/148,201 2021-02-11
PCT/US2022/016073 WO2022174012A1 (en) 2021-02-11 2022-02-11 INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS

Publications (1)

Publication Number Publication Date
CN116997339A true CN116997339A (zh) 2023-11-03

Family

ID=82837325

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280019484.7A Pending CN116997339A (zh) 2021-02-11 2022-02-11 作为治疗剂的cGAS活性抑制剂

Country Status (8)

Country Link
US (1) US20240174684A1 (https=)
EP (1) EP4291188A4 (https=)
JP (1) JP2024506904A (https=)
KR (1) KR20230144550A (https=)
CN (1) CN116997339A (https=)
AU (1) AU2022218787A1 (https=)
CA (1) CA3206520A1 (https=)
WO (1) WO2022174012A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (en) * 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
JP2025528113A (ja) * 2022-08-10 2025-08-26 ベルブルック ラボズ，エルエルシー 治療剤としてのｃＧＡＳ活性の阻害剤
KR20250103719A (ko) * 2022-11-09 2025-07-07 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors
WO2025233174A1 (en) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090028819A (ko) * 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
WO2008074445A1 (en) * 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
WO2013115167A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
EP3565810A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CA3125625A1 (en) * 2019-01-04 2020-07-09 Bellbrook Labs, Llc Inhibitors of cgas activity as therapeutic agents

Also Published As

Publication number Publication date
WO2022174012A1 (en) 2022-08-18
JP2024506904A (ja) 2024-02-15
KR20230144550A (ko) 2023-10-16
EP4291188A1 (en) 2023-12-20
US20240174684A1 (en) 2024-05-30
AU2022218787A1 (en) 2023-08-17
EP4291188A4 (en) 2025-01-08
CA3206520A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
CN116997339A (zh) 作为治疗剂的cGAS活性抑制剂
AU2019294835B2 (en) Ligands to cereblon (CRBN)
JP6959248B2 (ja) 癌治療用の４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−カルボニトリル誘導体
ES2660914T3 (es) Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
AU2005212409C1 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
JP2022547014A (ja) ヘテロ環式ｒｉｐ１キナーゼ阻害剤
RS65319B1 (sr) 8-cijano-5-piperidino-hinolini kao tlr7/8 antagonisti i njihova upotreba u lečenju imunoloških poremećaja
CN107428765B (zh) 用作irak抑制剂的哒嗪酮类大环化合物及其用途
BR112021002479A2 (pt) composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto
WO2018090939A1 (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
JP2022169796A (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
AU2022202886B2 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
RU2722383C2 (ru) Производные хромена в качестве ингибиторов фосфоинозитид-3-киназ
US12427146B2 (en) C-terminal SRC kinase inhibitors
CN107074856A (zh) CaMKII抑制剂及其用途
CN108463222A (zh) 用于治疗疾病的杂环化合物
JP7712941B2 (ja) トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
CN119698277A (zh) 作为治疗剂的cGAS活性抑制剂
CA2821777A1 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
CN115894376B (zh) 一种芳香族酰胺类化合物、药物组合物及其用途
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
ES2371358T3 (es) Compuesto de benzoimidazol capaz de inhibir prostaglandina d sintetasa.
HK40043591B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
BR112020013759A2 (pt) triazóis substituídos por heterociclilamino como moduladores de proteína cinase associada a rho

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination